

Walvax: A Leading Vaccine Developer & Producer in China

Walvax is one of China's most innovative and highest revenue generating companies for self-developed and produced vaccines, and ranked the world's 8th manufacturer by value in 2021 by WHO.



Key Financials

Market Cap:

5.3 billion USD (September 1, 2023)

2022 Revenue:

747.9 million USD (46.9% growth over 2021)

Manufacturers by Value:

Top 8 in 2021

(by WHO, excluding Covid vaccines)



Vaccine Products

8 licensed products

3 candidates in clinical stage

74 patents

18 countries exported to

3 vaccines in Morocco, Indonesia and Egypt **EPIs**



Collaborations

1st private Chinese vaccine company funded by Bill & Melinda Gates Foundation and CEPI

3 regional manufacturing partnerships in Morocco, Indonesia and Egypt



Talents

~ 2000 employees:

PhD and Master: ~200 staff Manufacture: 71%

General & Admin: 15% R&D: 8%

Sales: 6%



Fast Response mRNA Platform

By collaborating with Fudan University and RNACure and through Covid-19 vaccine R&D, Walvax has established a mRNA platform with 62-day lead time from DNA sequence to the first batch of sample.



Vaccine designed	Code of the mRNA Vaccine	Stage
mRNA Vaccine (1 strand)	RQ3013 (alpha + beta variant chimera)	BLA filing
	RQ3019 (Omicron.2/4/5)	-
	RQ3033 (XBB.1.5)	IND
mRNA Vaccine (2 strands)	RQ3025 (RQ3013+RQ3019)	IND



- SARS-CoV-2 variant mRNA vaccine (RQ3013): Target Product Profile -

Antigen	mRNA chimera of SARS-CoV-2 alpha and beta variants spike protein	
Administration Route	Intramuscular injection	
Indication	Prevention of COVID-19 caused by the infection of SARS-CoV-2	
Target Population	18 years and older	
Schedule	Primary series: 2-dose at Day 0 and Day 28	
	Booster dose: a single dose at least 6 months following the last COVID-19 vaccine	
Presentation	30 μg mRNA/0.15 mL/dose, single dose vial	
Self life & Storage	12 month, store at -20 °C or below	




RQ3013 Clinical Development Program





Manufacturing Readiness







Summary

- Walvax has established mRNA vaccine R&D and manufacturing platform through Covid-19 vaccine, fully validated its feasibility and fast response capability to encounter emerging Covid-19 variant endemics.
- This mRNA development platform will enable Walvax to develop more mRNA vaccines against other deadly infectious diseases and contribution more to global health.



